CoChat

Drug survival for ciclosporin A in a long-term daily practice cohort of adult patients with atopic dermatitis

Open access
van der Schaft, J., Politiek, K., van den Reek, J.M.P.A., Christoffers, W.A., Kievit, W., de Jong, E.M.G.J., Bruijnzeel-Koomen, C.A.F.M., Schuttelaar, M.L.A., de Bruin-Weller, M.S. · 2015 · British Journal of Dermatology
Cited by 78

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Long-term data of ciclosporin A (CsA) treatment in daily practice in patients with severe atopic dermatitis (AD) are lacking. OBJECTIVES: To perform a detailed analysis of drug survival, which is the length of time a patient continues to take a drug, for CsA in a long-term daily practice cohort of patients with AD. The secondary objective was to identify determinants of drug survival. METHODS: Data were extracted from a retrospective cohort of patients treated with CsA for AD. Drug survival was analysed using Kaplan-Meier survival curves. Determinants of drug survival were analysed using uni- and multivariate Cox regression analyses with backward selection. RESULTS: In total, 356 adult patients were analysed (386 patient-years). The overall drug survival rates were 34%, 18%, 12% and 4% after 1, 2, 3 and 6 years, respectively. Reasons for discontinuation were controlled AD (26·4%), side-effects (22·2%), ineffectiveness (16·3%), side-effects plus ineffectiveness (6·2%) or other reasons (11·0%). Older age was associated with a decreased drug survival related to controlled AD [hazard ratio (HR) 0·91]. Older age was also associated with a decreased drug survival related to side-effects (HR 1·14). An intermediate-to-high starting dose (> 3·5-5·0 mg kg(-1) daily) was associated with an increased drug survival related to ineffectiveness (HR 0·63). CONCLUSIONS: This is the first study on drug survival for CsA treatment in AD. Older age was associated with decreased drug survival related to controlled AD and side-effects. An intermediate-to-high starting dose was associated with an increased drug survival related to ineffectiveness.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/bjd.13730

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

See all 78

Metadata

Authors
van der Schaft, J., Politiek, K., van den Reek, J. M. P. A., Christoffers, W. A., Kievit, W., de Jong, E. M. G. J., Bruijnzeel-Koomen, C. A. F. M., Schuttelaar, M. L. A., & de Bruin-Weller, M. S.
Venue
British Journal of Dermatology
Published
2015-05-11
Volume
172
Issue
6
Pages
1621-1627
ISSN
0007-0963 (ISSN-L)
OpenAlex
W2098889816
Cited by
78
References
3
FWCI
8.52
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Drug survival for ciclosporin A in a long-term daily practice cohort of adult patients with atopic dermatitis. https://app.cochat.ai/papers/10.1111/bjd.13730
The paper
van der Schaft, J., Politiek, K., van den Reek, J. M. P. A., Christoffers, W. A., Kievit, W., de Jong, E. M. G. J., Bruijnzeel-Koomen, C. A. F. M., Schuttelaar, M. L. A., & de Bruin-Weller, M. S. (2015). Drug survival for ciclosporin A in a long-term daily practice cohort of adult patients with atopic dermatitis. British Journal of Dermatology. https://doi.org/10.1111/bjd.13730

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.